Ozgur Ozdemir
Research Interests
Ozgur Ozdemir has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Ilker Eryilmaz
Antalya Training and Research Hospital, Department of Obstetrics and Gynecology, Antalya, Turkey
1 shared publication - Derya Erturk
Antalya Training and Research Hospital, Department of Obstetrics and Gynecology, Antalya, Turkey
1 shared publication - Durmus Onder
Antalya Training and Research Hospital, Department of Obstetrics and Gynecology, Antalya, Turkey
1 shared publication - Güzin Aykal
Department of Biochemistry, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey
1 shared publication - Meryem Busra Birsen
Antalya Training and Research Hospital, Department of Obstetrics and Gynecology, Antalya, Turkey
1 shared publication - Zeynep Ozturk Inal
Konya City Hospital
1 shared publication
Latest Publications
- Open Access
- 20 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (38) , e39695
An evaluation of serum blood parameters and amyloid-A levels in women with hyperemesis gravidarum; A prospective observational study
This study aimed to investigate whether serum amyloid A (AA) level can be used as a biomarker in women with hyperemesis gravidarum (HEG). This prospective observational study was conducted at the Antalya Training and Research Hospital Gynecology and Obstetrics Clinic, Türkiye, between July and December 2023. Forty women diagnosed with HEG and 40 healthy women were included. No statistically significant differences were observed between the groups in terms of sociodemographic data such as age, body mass index, family history, educational status, economic level, place of residence, occupation, smoking and alcohol use, or drug habits. However, obstetric characteristics such as number of miscarriages, number of dilatation curettages, and gestational age and laboratory values including complete blood count, hematocrit, leukocyte, neutrophil, lymphocyte, platelet, free T4, albumin, alanine aminotransferase, aspartate aminotransferase, urea, creatinine, hs-C-reactive protein, and sodium (P > .05) all differed significantly. In addition, significant differences were observed between the HEG and healthy groups in terms of numbers of gravidities (2 [1–3] vs 1 [0–1], respectively, P < .001), numbers of parities (1 [0–1] vs 1 [0–1], P < .001), numbers of living children (1 [0–2] vs 1 [0–1], P < .001), presenting complaints (nausea 0 [0%], nausea + vomiting 0 [0%], none 40 [100.0%] vs nausea 27 [67.5%], nausea + vomiting 13 [32.5%], none 0 [0%], P < .001), serum thyroid-stimulating hormone (1.16 ± 0.56 vs 1.81 ± 0.624, P = .004), potassium (4.1 ± 0.7 vs 3.8 ± 0.2, P = .001), and AA values (7.29 ± 2.61 vs 10.74 ± 3.04, P < .001). At receiver operating characteristic analysis, the area under the curve (AUC: 0.881) was statistically significant for serum AA (P: <.001), with a cutoff value of ≥ 8.79 ([95% confidence interval] 0.743–0.919, sensitivity 87.4%, specificity 80.2%). The positive predictive value of serum AA was 81.1% and the negative predictive value was 80.4%. The study results showed that serum AA can be used as a diagnostic biomarker in HEG. Prospective studies involving more participants are now required to confirm our results.
- 20 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (38) , e39695
Open AccessAn evaluation of serum blood parameters and amyloid-A levels in women with hyperemesis gravidarum; A prospective observational study
This study aimed to investigate whether serum amyloid A (AA) level can be used as a biomarker in women with hyperemesis gravidarum (HEG). This prospective observational study was conducted at the Antalya Training and Research Hospital Gynecology and Obstetrics Clinic, Türkiye, between July and December 2023. Forty women diagnosed with HEG and 40 healthy women were included. No statistically significant differences were observed between the groups in terms of sociodemographic data such as age, body mass index, family history, educational status, economic level, place of residence, occupation, smoking and alcohol use, or drug habits. However, obstetric characteristics such as number of miscarriages, number of dilatation curettages, and gestational age and laboratory values including complete blood count, hematocrit, leukocyte, neutrophil, lymphocyte, platelet, free T4, albumin, alanine aminotransferase, aspartate aminotransferase, urea, creatinine, hs-C-reactive protein, and sodium (P > .05) all differed significantly. In addition, significant differences were observed between the HEG and healthy groups in terms of numbers of gravidities (2 [1–3] vs 1 [0–1], respectively, P < .001), numbers of parities (1 [0–1] vs 1 [0–1], P < .001), numbers of living children (1 [0–2] vs 1 [0–1], P < .001), presenting complaints (nausea 0 [0%], nausea + vomiting 0 [0%], none 40 [100.0%] vs nausea 27 [67.5%], nausea + vomiting 13 [32.5%], none 0 [0%], P < .001), serum thyroid-stimulating hormone (1.16 ± 0.56 vs 1.81 ± 0.624, P = .004), potassium (4.1 ± 0.7 vs 3.8 ± 0.2, P = .001), and AA values (7.29 ± 2.61 vs 10.74 ± 3.04, P < .001). At receiver operating characteristic analysis, the area under the curve (AUC: 0.881) was statistically significant for serum AA (P: <.001), with a cutoff value of ≥ 8.79 ([95% confidence interval] 0.743–0.919, sensitivity 87.4%, specificity 80.2%). The positive predictive value of serum AA was 81.1% and the negative predictive value was 80.4%. The study results showed that serum AA can be used as a diagnostic biomarker in HEG. Prospective studies involving more participants are now required to confirm our results.